Anti-Programmed Cell Death Protein 1 (PD-1) Immunotherapy for Metastatic Hepatocellular Carcinoma After Liver Transplantation: A Report of Three Cases

The treatment of recurrent hepatocellular carcinoma (HCC) after liver transplantation is difficult due to the lack of effective treatment options. The available evidence on the emerging immunotherapy in liver transplantation is based on anecdotal experiences and requires additional investigations. T...

Descripción completa

Detalles Bibliográficos
Autores principales: Al Jarroudi, Ouissam, Ulusakarya, Ayhan, Almohamad, Wathek, Afqir, Said, Morere, Jean-Francois
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2020
Materias:
Gastroenterology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7586420/
https://www.ncbi.nlm.nih.gov/pubmed/33133796
http://dx.doi.org/10.7759/cureus.11150
_version_ 1783599993616072704
author Al Jarroudi, Ouissam
Ulusakarya, Ayhan
Almohamad, Wathek
Afqir, Said
Morere, Jean-Francois
author_facet Al Jarroudi, Ouissam
Ulusakarya, Ayhan
Almohamad, Wathek
Afqir, Said
Morere, Jean-Francois
author_sort Al Jarroudi, Ouissam
collection PubMed
description The treatment of recurrent hepatocellular carcinoma (HCC) after liver transplantation is difficult due to the lack of effective treatment options. The available evidence on the emerging immunotherapy in liver transplantation is based on anecdotal experiences and requires additional investigations. To determine the efficacy and safety of immunotherapy in liver transplant recipients, we report three cases of recurrent metastatic HCC after liver transplantation who were treated with nivolumab as off-label salvage therapy.
format Online
Article
Text
id pubmed-7586420
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-75864202020-10-29 Anti-Programmed Cell Death Protein 1 (PD-1) Immunotherapy for Metastatic Hepatocellular Carcinoma After Liver Transplantation: A Report of Three Cases Al Jarroudi, Ouissam Ulusakarya, Ayhan Almohamad, Wathek Afqir, Said Morere, Jean-Francois Cureus Gastroenterology The treatment of recurrent hepatocellular carcinoma (HCC) after liver transplantation is difficult due to the lack of effective treatment options. The available evidence on the emerging immunotherapy in liver transplantation is based on anecdotal experiences and requires additional investigations. To determine the efficacy and safety of immunotherapy in liver transplant recipients, we report three cases of recurrent metastatic HCC after liver transplantation who were treated with nivolumab as off-label salvage therapy. Cureus 2020-10-25 /pmc/articles/PMC7586420/ /pubmed/33133796 http://dx.doi.org/10.7759/cureus.11150 Text en Copyright © 2020, Al Jarroudi et al. http://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Gastroenterology
Al Jarroudi, Ouissam
Ulusakarya, Ayhan
Almohamad, Wathek
Afqir, Said
Morere, Jean-Francois
Anti-Programmed Cell Death Protein 1 (PD-1) Immunotherapy for Metastatic Hepatocellular Carcinoma After Liver Transplantation: A Report of Three Cases
title Anti-Programmed Cell Death Protein 1 (PD-1) Immunotherapy for Metastatic Hepatocellular Carcinoma After Liver Transplantation: A Report of Three Cases
title_full Anti-Programmed Cell Death Protein 1 (PD-1) Immunotherapy for Metastatic Hepatocellular Carcinoma After Liver Transplantation: A Report of Three Cases
title_fullStr Anti-Programmed Cell Death Protein 1 (PD-1) Immunotherapy for Metastatic Hepatocellular Carcinoma After Liver Transplantation: A Report of Three Cases
title_full_unstemmed Anti-Programmed Cell Death Protein 1 (PD-1) Immunotherapy for Metastatic Hepatocellular Carcinoma After Liver Transplantation: A Report of Three Cases
title_short Anti-Programmed Cell Death Protein 1 (PD-1) Immunotherapy for Metastatic Hepatocellular Carcinoma After Liver Transplantation: A Report of Three Cases
title_sort anti-programmed cell death protein 1 (pd-1) immunotherapy for metastatic hepatocellular carcinoma after liver transplantation: a report of three cases
topic Gastroenterology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7586420/
https://www.ncbi.nlm.nih.gov/pubmed/33133796
http://dx.doi.org/10.7759/cureus.11150
work_keys_str_mv AT aljarroudiouissam antiprogrammedcelldeathprotein1pd1immunotherapyformetastatichepatocellularcarcinomaafterlivertransplantationareportofthreecases
AT ulusakaryaayhan antiprogrammedcelldeathprotein1pd1immunotherapyformetastatichepatocellularcarcinomaafterlivertransplantationareportofthreecases
AT almohamadwathek antiprogrammedcelldeathprotein1pd1immunotherapyformetastatichepatocellularcarcinomaafterlivertransplantationareportofthreecases
AT afqirsaid antiprogrammedcelldeathprotein1pd1immunotherapyformetastatichepatocellularcarcinomaafterlivertransplantationareportofthreecases
AT morerejeanfrancois antiprogrammedcelldeathprotein1pd1immunotherapyformetastatichepatocellularcarcinomaafterlivertransplantationareportofthreecases

Ejemplares similares